Pneumonia has been recognized as a common and potentially lethalcondition for nearly two centuries. Comprehensive studies ofthe disease in the pre-antibiotic era showed mortality ratesof about 1 per 1000 per year; over 80 percent of the cases weredue to Streptococcus pneumoniae, and mortality rates were generallyreported at 20 to 40 percent.1,2 Community-acquired pneumonia(as distinguished from that acquired nosocomially or in a nursinghome) continues to be a common and serious illness. Currentestimates for the United States are 4 million cases annually,an attack rate of 12 per 1000 adults per year, about 600,000. . . [Full Text of this Article]
Clinical Diagnosis
Evaluation
Chest Radiography
Identification of Pathogens
Assessment of Severity
Parapneumonic Effusions
Microbial Pathogens
Treatment
Source Information
From the Johns Hopkins University School of Medicine, Baltimore.
Address reprint requests to Dr. Bartlett at the Division of Infectious Diseases, Ross Research Bldg., Rm. 1159, 720 Rutland Ave., Baltimore, MD 21205.
References
Related Letters:
Community-Acquired Pneumonia
Mandell L. A., Niederman M. S., Boersma W. G., Holloway Y., Halm E. A., Metlay J. P., Singer D. E., Fine M. J., Bartlett J. G.
Extract |
Full Text
N Engl J Med 1996;
334:861-863, Mar 28, 1996.
Correspondence
This article has been cited by other articles:
Pilotto, A., Addante, F., Ferrucci, L., Leandro, G., D'Onofrio, G., Corritore, M., Niro, V., Scarcelli, C., Dallapiccola, B., Franceschi, M.
(2009). The Multidimensional Prognostic Index Predicts Short- and Long-Term Mortality in Hospitalized Geriatric Patients With Pneumonia. J Gerontol A Biol Sci Med Sci
64A: 880-887
[Abstract][Full Text]
Jiang, L.-J., Wang, M., Or, Y. S.
(2009). Pharmacokinetics of EDP-420 after Ascending Single Oral Doses in Healthy Adult Volunteers. Antimicrob. Agents Chemother.
53: 1786-1792
[Abstract][Full Text]
Hayakawa, K., Tateda, K., Fuse, E. T., Matsumoto, T., Akasaka, Y., Ishii, T., Nakayama, T., Taniguchi, M., Kaku, M., Standiford, T. J., Yamaguchi, K.
(2008). Paradoxically high resistance of natural killer T (NKT) cell-deficient mice to Legionella pneumophila: another aspect of NKT cells for modulation of host responses. J Med Microbiol
57: 1340-1348
[Abstract][Full Text]
Ge, Y., Biek, D., Talbot, G. H., Sahm, D. F.
(2008). In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States. Antimicrob. Agents Chemother.
52: 3398-3407
[Abstract][Full Text]
Lodise, T. P., Kinzig-Schippers, M., Drusano, G. L., Loos, U., Vogel, F., Bulitta, J., Hinder, M., Sorgel, F.
(2008). Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. Antimicrob. Agents Chemother.
52: 1945-1951
[Abstract][Full Text]
Lodise, T. P., Kwa, A., Cosler, L., Gupta, R., Smith, R. P.
(2007). Comparison of {beta}-Lactam and Macrolide Combination Therapy versus Fluoroquinolone Monotherapy in Hospitalized Veterans Affairs Patients with Community-Acquired Pneumonia. Antimicrob. Agents Chemother.
51: 3977-3982
[Abstract][Full Text]
Salt, P., Banner, C., Oh, S., Yu, L.-m., Lewis, S., Pan, D., Griffiths, D., Ferry, B., Pollard, A.
(2007). Social Mixing with Other Children during Infancy Enhances Antibody Response to a Pneumococcal Conjugate Vaccine in Early Childhood. CVI
14: 593-599
[Abstract][Full Text]
Nyamande, K, Lalloo, U G, Vawda, F
(2007). Comparison of plain chest radiography and high-resolution CT in human immunodeficiency virus infected patients with community-acquired pneumonia: a sub-Saharan Africa study. Br. J. Radiol.
80: 302-306
[Abstract][Full Text]
Diaz, A., Barria, P., Niederman, M., Restrepo, M. I., Dreyse, J., Fuentes, G., Couble, B., Saldias, F.
(2007). Etiology of Community-Acquired Pneumonia in Hospitalized Patients in Chile: The Increasing Prevalence of Respiratory Viruses Among Classic Pathogens. Chest
131: 779-787
[Abstract][Full Text]
Hopstaken, R M, Coenen, S, Butler, C C, Nelemans, P, Muris, J W M, Rinkens, P E L M, Kester, A D M, Dinant, G J
(2006). Prognostic factors and clinical outcome in acute lower respiratory tract infections: a prospective study in general practice. Fam Pract
23: 512-519
[Abstract][Full Text]
Fukuda, Y., Yanagihara, K., Higashiyama, Y., Miyazaki, Y., Hirakata, Y., Mukae, H., Tomono, K., Mizuta, Y., Tsukamoto, K., Kohno, S.
(2006). Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J
27: 1020-1025
[Abstract][Full Text]
Hopstaken, R. M, Butler, C. C, Muris, J. W M, Knottnerus, J A., Kester, A. D M, Rinkens, P. E L M, Dinant, G.-J.
(2006). Do clinical findings in lower respiratory tract infection help general practitioners prescribe antibiotics appropriately? An observational cohort study in general practice. Fam Pract
23: 180-187
[Abstract][Full Text]
Marrer, E., Satoh, A. T., Johnson, M. M., Piddock, L. J. V., Page, M. G. P.
(2006). Global Transcriptome Analysis of the Responses of a Fluoroquinolone-Resistant Streptococcus pneumoniae Mutant and Its Parent to Ciprofloxacin. Antimicrob. Agents Chemother.
50: 269-278
[Abstract][Full Text]
Weiss, K., Tillotson, G. S.
(2005). The Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired Pneumonia. Chest
128: 940-946
[Abstract][Full Text]
van der Meer, V., Neven, A. K., van den Broek, P. J, Assendelft, W. J J
(2005). Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ
331: 26-
[Abstract][Full Text]
Yershov, A. L., Jordan, B. S., Guymon, C. H., Dubick, M. A.
(2005). Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model. Eur Respir J
25: 693-700
[Abstract][Full Text]
Gracia, M., Martinez-Marin, C., Huelves, L., Gimenez, M. J., Aguilar, L., Carcas, A., Ponte, C., Soriano, F.
(2005). Pulmonary Damage and Bacterial Load in Assessment of the Efficacy of Simulated Human Treatment-Like Amoxicillin (2,000 Milligrams) Therapy of Experimental Pneumococcal Pneumonia Caused by Strains for Which Amoxicillin MICs Differ. Antimicrob. Agents Chemother.
49: 996-1001
[Abstract][Full Text]
Hawn, T. R., Verbon, A., Janer, M., Zhao, L. P., Beutler, B., Aderem, A.
(2005). Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc. Natl. Acad. Sci. USA
102: 2487-2489
[Abstract][Full Text]
Carratala, J., Fernandez-Sabe, N., Ortega, L., Castellsague, X., Roson, B., Dorca, J., Fernandez-Aguera, A., Verdaguer, R., Martinez, J., Manresa, F., Gudiol, F.
(2005). Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia: A Randomized Trial in Low-Risk Patients. ANN INTERN MED
142: 165-172
[Abstract][Full Text]
Paganin, F., Lilienthal, F., Bourdin, A., Lugagne, N., Tixier, F., Genin, R., Yvin, J-L.
(2004). Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J
24: 779-785
[Abstract][Full Text]
Branger, J., Florquin, S., Knapp, S., Leemans, J. C., Pater, J. M., Speelman, P., Golenbock, D. T., van der Poll, T.
(2004). LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia. Int Immunol
16: 1605-1611
[Abstract][Full Text]
Laheij, R. J. F., Sturkenboom, M. C. J. M., Hassing, R.-J., Dieleman, J., Stricker, B. H. C., Jansen, J. B. M. J.
(2004). Risk of Community-Acquired Pneumonia and Use of Gastric Acid-Suppressive Drugs. JAMA
292: 1955-1960
[Abstract][Full Text]
Tiemei, Z., Xiangqun, F., Youning, L.
(2004). Resistance Phenotypes and Genotypes of Erythromycin-Resistant Streptococcus pneumoniae Isolates in Beijing and Shenyang, China. Antimicrob. Agents Chemother.
48: 4040-4041
[Abstract][Full Text]
Opitz, B., Puschel, A., Schmeck, B., Hocke, A. C., Rosseau, S., Hammerschmidt, S., Schumann, R. R., Suttorp, N., Hippenstiel, S.
(2004). Nucleotide-binding Oligomerization Domain Proteins Are Innate Immune Receptors for Internalized Streptococcus pneumoniae. J. Biol. Chem.
279: 36426-36432
[Abstract][Full Text]
Yasuda, H., Sasaki, T., Yamaya, M., Ebihara, S., Maruyama, M., Kanda, A., Sasaki, H.
(2004). Increased Arteriovenous Carboxyhemoglobin Differences in Patients With Inflammatory Pulmonary Diseases. Chest
125: 2160-2168
[Abstract][Full Text]
Faich, G. A, Morganroth, J., Whitehouse, A. B, Brar, J. S, Arcuri, P., Kowalsky, S. F, Haverstock, D. C, Celesk, R. A, Church, D. A
(2004). Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections. The Annals of Pharmacotherapy
38: 749-754
[Abstract][Full Text]
Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Schmitt-Hoffmann, A., Schleimer, M., Shapiro, S.
(2004). Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal Pneumonia. Antimicrob. Agents Chemother.
48: 1105-1111
[Abstract][Full Text]
Roson, B., Carratala, J., Fernandez-Sabe, N., Tubau, F., Manresa, F., Gudiol, F.
(2004). Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia. Arch Intern Med
164: 502-508
[Abstract][Full Text]
Branger, J., Knapp, S., Weijer, S., Leemans, J. C., Pater, J. M., Speelman, P., Florquin, S., van der Poll, T.
(2004). Role of Toll-Like Receptor 4 in Gram-Positive and Gram-Negative Pneumonia in Mice. Infect. Immun.
72: 788-794
[Abstract][Full Text]
Goss, C. H., Rubenfeld, G. D., Park, D. R., Sherbin, V. L., Goodman, M. S., Root, R. K.
(2003). Cost and Incidence of Social Comorbidities in Low-Risk Patients With Community-Acquired Pneumonia Admitted to a Public Hospital. Chest
124: 2148-2155
[Abstract][Full Text]
Yamazaki, K., Ogura, S., Ishizaka, A., Oh-hara, T., Nishimura, M.
(2003). Bronchoscopic Microsampling Method for Measuring Drug Concentration in Epithelial Lining Fluid. Am. J. Respir. Crit. Care Med.
168: 1304-1307
[Abstract][Full Text]
Hawn, T. R., Verbon, A., Lettinga, K. D., Zhao, L. P., Li, S. S., Laws, R. J., Skerrett, S. J., Beutler, B., Schroeder, L., Nachman, A., Ozinsky, A., Smith, K. D., Aderem, A.
(2003). A Common Dominant TLR5 Stop Codon Polymorphism Abolishes Flagellin Signaling and Is Associated with Susceptibility to Legionnaires' Disease. JEM
198: 1563-1572
[Abstract][Full Text]
Garau, J., Twynholm, M., Garcia-Mendez, E., Siquier, B., Rivero, A., the 557 Clinical Study Group,
(2003). Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother
52: 826-836
[Abstract][Full Text]
Clark, J. P., Langston, E.
(2003). Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting. Mayo Clin Proc.
78: 1113-1124
[Abstract]
Drummond, M. F., Becker, D. L., Hux, M., Chancellor, J. V. M., Duprat-Lomon, I., Kubin, R., Sagnier, P.-P.
(2003). An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia. Chest
124: 526-535
[Abstract][Full Text]
Wattanathum, A., Chaoprasong, C., Nunthapisud, P., Chantaratchada, S., Limpairojn, N., Jatakanon, A., Chanthadisai, N.
(2003). Community-Acquired Pneumonia in Southeast Asia: The Microbial Differences Between Ambulatory and Hospitalized Patients. Chest
123: 1512-1519
[Abstract][Full Text]
Jackson, L. A., Neuzil, K. M., Yu, O., Benson, P., Barlow, W. E., Adams, A. L., Hanson, C. A., Mahoney, L. D., Shay, D. K., Thompson, W. W., the Vaccine Safety Datalink,
(2003). Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults. NEJM
348: 1747-1755
[Abstract][Full Text]
Singer, M. E., Harding, I., Jacobs, M. R., Jaffe, D. H.
(2003). Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother
51: 1269-1282
[Abstract][Full Text]
Pistelli, R., Lange, P., Miller, D.L.
(2003). Determinants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidity. Eur Respir J
21: 10S-14s
[Abstract][Full Text]
Schultz, M. J., Knapp, S., Florquin, S., Pater, J., Takeda, K., Akira, S., van der Poll, T.
(2003). Interleukin-18 Impairs the Pulmonary Host Response to Pseudomonas aeruginosa. Infect. Immun.
71: 1630-1634
[Abstract][Full Text]
Luna, C. M.
(2003). Blood Cultures in Community-Acquired Pneumonia: Are We Ready To Quit?. Chest
123: 977-978
[Full Text]
Fogarty, C. M., Kohno, S., Buchanan, P., Aubier, M., Baz, M.
(2003). Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother
51: 947-955
[Abstract][Full Text]
Zalacain, R., Torres, A., Celis, R., Blanquer, J., Aspa, J., Esteban, L., Menendez, R., Blanquer, R., Borderias, L.
(2003). Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J
21: 294-302
[Abstract][Full Text]
Metlay, J. P., Fine, M. J.
(2003). Testing Strategies in the Initial Management of Patients with Community-Acquired Pneumonia. ANN INTERN MED
138: 109-118
[Abstract][Full Text]
Ellbogen, M. H., Olsen, K. M., Gentry-Nielsen, M. J., Preheim, L. C.
(2003). Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother
51: 83-91
[Abstract][Full Text]
Halm, E. A., Teirstein, A. S.
(2002). Management of Community-Acquired Pneumonia. NEJM
347: 2039-2045
[Full Text]
Pepper, P. V., Owens, D. K.
(2002). Cost-Effectiveness of the Pneumococcal Vaccine in Healthy Younger Adults. Med Decis Making
22: S45-S57
[Abstract]
Lamping, D. L., Schroter, S., Marquis, P., Marrel, A., Duprat-Lomon, I., Sagnier, P.-P.
(2002). The Community-Acquired Pneumonia Symptom Questionnaire* : A New, Patient-Based Outcome Measure To Evaluate Symptoms in Patients With Community-Acquired Pneumonia. Chest
122: 920-929
[Abstract][Full Text]
Jones, M. E., Karlowsky, J. A., Blosser-Middleton, R., Critchley, I. A., Karginova, E., Thornsberry, C., Sahm, D. F.
(2002). Longitudinal Assessment of Antipneumococcal Susceptibility in the United States. Antimicrob. Agents Chemother.
46: 2651-2655
[Abstract][Full Text]
Gentry-Nielsen, M. J., Olsen, K. M., Preheim, L. C.
(2002). Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia. Antimicrob. Agents Chemother.
46: 1345-1351
[Abstract][Full Text]
Ewig, S., Schlochtermeier, M., Goke, N., Niederman, M. S.
(2002). Applying Sputum as a Diagnostic Tool in Pneumonia* : Limited Yield, Minimal Impact on Treatment Decisions. Chest
121: 1486-1492
[Abstract][Full Text]
Yague, G., Morris, J. E., Pan, X.-S., Gould, K. A., Fisher, L. M.
(2002). Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones. Antimicrob. Agents Chemother.
46: 413-419
[Abstract][Full Text]
Critchley, I. A., Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Murfitt, K., Sahm, D. F.
(2002). Activities of Faropenem, an Oral {beta}-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother.
46: 550-555
[Abstract][Full Text]
Morris, J. E., Pan, X.-S., Fisher, L. M.
(2002). Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae: Role of the C-5 Group in Target Specificity. Antimicrob. Agents Chemother.
46: 582-585
[Abstract][Full Text]
HERKNER, H., MULLER, M. R., KREISCHITZ, N., MAYER, B. X., FROSSARD, M., JOUKHADAR, C., KLEIN, N., LACKNER, E., MULLER, M.
(2002). Closed-Chest Microdialysis to Measure Antibiotic Penetration into Human Lung Tissue. Am. J. Respir. Crit. Care Med.
165: 273-276
[Abstract][Full Text]
Pan, X.-S., Yague, G., Fisher, L. M.
(2001). Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis, Intracellular Levels, and Phenotypes of Wild-Type and Mutant Proteins. Antimicrob. Agents Chemother.
45: 3140-3147
[Abstract][Full Text]
File, T. M. Jr, Schlemmer, B., Garau, J., Cupo, M., Young, C., the 049 Clinical Study Group,
(2001). Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother
48: 67-74
[Abstract][Full Text]
Fantin, B., Aubert, J. P., Unger, P., Lecoeur, H., Carbon, C.
(2001). Clinical Evaluation of the Management of Community-Acquired Pneumonia by General Practitioners in France. Chest
120: 185-192
[Abstract][Full Text]
Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., Martinez, F., Marrie, T. J., Plouffe, J. F., Ramirez, J., Sarosi, G. A., Torres, A., Wilson, R., Yu, V. L.
(2001). Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am. J. Respir. Crit. Care Med.
163: 1730-1754
[Full Text]
Cubbon, M. D., Masterton, R. G.
(2000). New quinolones--a fresh answer to the pneumococcus. J Antimicrob Chemother
46: 869-872
[Full Text]
Bast, D. J., Low, D. E., Duncan, C. L., Kilburn, L., Mandell, L. A., Davidson, R. J., de Azavedo, J. C. S.
(2000). Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae: Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance. Antimicrob. Agents Chemother.
44: 3049-3054
[Abstract][Full Text]
Heaton, V. J., Ambler, J. E., Fisher, L. M.
(2000). Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro. Antimicrob. Agents Chemother.
44: 3112-3117
[Abstract][Full Text]
Plouffe, J., Schwartz, D. B., Kolokathis, A., Sherman, B. W., Arnow, P. M., Gezon, J. A., Suh, B., Anzuetto, A., Greenberg, R. N., Niederman, M., Paladino, J. A., Ramirez, J. A., Inverso, J., Knirsch, C. A., the Azithromycin Intravenous Clinical Trials Group,
(2000). Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia. Antimicrob. Agents Chemother.
44: 1796-1802
[Abstract][Full Text]
Shapiro, D. S., Mark, E. J.
(2000). Case 14-2000- A 60-Year-Old Farm Worker with Bilateral Pneumonia. NEJM
342: 1430-1438
[Full Text]
Feagan, B.
(2000). Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. CMAJ
162: 1415-1420
Marrie, T. J., Lau, C. Y., Wheeler, S. L., Wong, C. J., Vandervoort, M. K., Feagan, B. G., for the CAPITAL Study Investigators,
(2000). A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia. JAMA
283: 749-755
[Abstract][Full Text]
Alovero, F. L., Pan, X.-S., Morris, J. E., Manzo, R. H., Fisher, L. M.
(2000). Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase. Antimicrob. Agents Chemother.
44: 320-325
[Abstract][Full Text]
Harwell, J. I., Brown, R. B.
(2000). The Drug-Resistant Pneumococcus: Clinical Relevance, Therapy, and Prevention. Chest
117: 530-541
[Abstract][Full Text]
Thornsberry, C., Jones, M. E., Hickey, M. L., Mauriz, Y., Kahn, J., Sahm, D. F.
(1999). Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother
44: 749-759
[Abstract][Full Text]
Gleason, P. P., Meehan, T. P., Fine, J. M., Galusha, D. H., Fine, M. J.
(1999). Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With Pneumonia. Arch Intern Med
159: 2562-2572
[Abstract][Full Text]
Lacy, M. K., Nicolau, D. P., Banevicius, M. A., Nightingale, C. H., Quintiliani, R.
(1999). Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniaein a murine sepsis model. J Antimicrob Chemother
44: 477-481
[Abstract][Full Text]
Moola, S., Hagberg, L., Churchyard, G. A., Dylewski, J. S., Sedani, S., Staley, H.
(1999). A Multicenter Study of Grepafloxacin and Clarithromycin in the Treatment of Patients With Community-Acquired Pneumonia. Chest
116: 974-983
[Abstract][Full Text]
Amsden, G. W.
(1999). Pneumococcal macrolide resistance—myth or reality?. J Antimicrob Chemother
44: 1-6
[Full Text]
O'Brien, A. D., Standiford, T. J., Bucknell, K. A., Wilcoxen, S. E., Paine, R. III
(1999). Role of alveolar epithelial cell intercellular adhesion molecule-1 in host defense against Klebsiella pneumoniae. Am. J. Physiol. Lung Cell. Mol. Physiol.
276: L961-L970
[Abstract][Full Text]
Fine, M. J., Stone, R. A., Singer, D. E., Coley, C. M., Marrie, T. J., Lave, J. R., Hough, L. J., Obrosky, D. S., Schulz, R., Ricci, E. M., Rogers, J. C., Kapoor, W. N.
(1999). Processes and Outcomes of Care for Patients With Community-Acquired Pneumonia: Results From the Pneumonia Patient Outcomes Research Team (PORT) Cohort Study. Arch Intern Med
159: 970-980
[Abstract][Full Text]
Pan, X.-S., Fisher, L. M.
(1999). Streptococcus pneumoniae DNA Gyrase and Topoisomerase IV: Overexpression, Purification, and Differential Inhibition by Fluoroquinolones. Antimicrob. Agents Chemother.
43: 1129-1136
[Abstract][Full Text]
Grossman, R. F., Campbell, D. A., Landis, S. J., Garber, G. E., Murray, G., Stiver, H. G., Saginur, R., McIvor, R. A., Laforge, J., Rotstein, C., Dubois, J., Rivard, M., Boulerice, F.
(1999). Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother
43: 549-554
[Abstract][Full Text]
Lacy, M. K., Lu, W., Xu, X., Tessier, P. R., Nicolau, D. P., Quintiliani, R., Nightingale, C. H.
(1999). Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against Streptococcus pneumoniae in an In Vitro Model of Infection. Antimicrob. Agents Chemother.
43: 672-677
[Abstract][Full Text]
García, A., Rosón, B., Pérez, J. L., Verdaguer, R., Dorca, J., Carratalà, J., Casanova, A., Manresa, F., Gudiol, F.
(1999). Usefulness of PCR and Antigen Latex Agglutination Test with Samples Obtained by Transthoracic Needle Aspiration for Diagnosis of Pneumococcal Pneumonia. J. Clin. Microbiol.
37: 709-714
[Abstract][Full Text]
Borja, J., Jane;, F., Zervos, M. J.
(1999). Cefepime versus Ceftriaxone for Empiric Treatment of Hospitalized Patients with Community-Acquired Pneumonia. Antimicrob. Agents Chemother.
43: 436-437
[Full Text]
Gröndahl, B., Puppe, W., Hoppe, A., Kühne, I., Weigl, J. A. I., Schmitt, H.-J.
(1999). Rapid Identification of Nine Microorganisms Causing Acute Respiratory Tract Infections by Single-Tube Multiplex Reverse Transcription-PCR: Feasibility Study. J. Clin. Microbiol.
37: 1-7
[Abstract][Full Text]
Florida Medical Quality Assurance, Inc.,
(1998). Quality of Care Improvements for Patients with Pneumonia. Eval Health Prof
21: 514-524
[Abstract]
Pan, X.-S., Fisher, L. M.
(1998). DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae. Antimicrob. Agents Chemother.
42: 2810-2816
[Abstract][Full Text]
Atlas, S. J., Benzer, T. I., Borowsky, L. H., Chang, Y., Burnham, D. C., Metlay, J. P., Halm, E. A., Singer, D. E.
(1998). Safely Increasing the Proportion of Patients With Community-Acquired Pneumonia Treated as Outpatients: An Interventional Trial. Arch Intern Med
158: 1350-1356
[Abstract][Full Text]
Sax, P. E., Klein, R. S., Mark, E. J.
(1998). Case 16-1998- Pneumonia and the Acute Respiratory Distress Syndrome in a 24-Year-Old Man. NEJM
338: 1527-1535
[Full Text]
Halm, E. A., Fine, M. J., Marrie, T. J., Coley, C. M., Kapoor, W. N., Obrosky, D. S., Singer, D. E.
(1998). Time to Clinical Stability in Patients Hospitalized With Community-Acquired Pneumonia: Implications for Practice Guidelines. JAMA
279: 1452-1457
[Abstract][Full Text]
Marston, B. J., Plouffe, J. F., File, T. M. Jr, Hackman, B. A., Salstrom, S.-J., Lipman, H. B., Kolczak, M. S., Breiman, R. F.
(1997). Incidence of Community-Acquired Pneumonia Requiring Hospitalization: Results of a Population-Based Active Surveillance Study in Ohio. Arch Intern Med
157: 1709-1718
[Abstract]
Gleason, P. P., Kapoor, W. N., Stone, R. A., Lave, J. R., Obrosky, D. S., Schulz, R., Singer, D. E., Coley, C. M., Marrie, T. J., Fine, M. J.
(1997). Medical Outcomes and Antimicrobial Costs With the Use of the American Thoracic Society Guidelines for Outpatients With Community-Acquired Pneumonia. JAMA
278: 32-39
[Abstract]
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., Kapoor, W. N.
(1997). A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia. NEJM
336: 243-250
[Abstract][Full Text]
Mandell, L. A., Niederman, M. S., Boersma, W. G., Holloway, Y., Halm, E. A., Metlay, J. P., Singer, D. E., Fine, M. J., Bartlett, J. G.
(1996). Community-Acquired Pneumonia. NEJM
334: 861-863
[Full Text]
Rothschild, E., Rauss, A., Danan, G.
(1996). Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. BMJ
312: 778-778
[Full Text]
Previous
